IVB injections successful for mCNV


Intravitreal bevacizumab (IVB) provide sustained and effective treatment for myopic choroidal neovascularization (mCNV).

Intravitreal bevacizumab (IVB) provide sustained and effective treatment for myopic choroidal neovascularization (mCNV).

The prospective case series, led by Dr Magda Gharbiya, Department of Ophthalmology, Sapienza University – Umberto I Hospital, Rome, Italy, consisted of 32 eyes of 30 mCNV patients.

Each participant was administered three monthly 1.25 mg IVB injections. Regression analysis was used to measure the prognostic factors of age, axial length, baseline BCVA, pre-treatment CNV area, CNV location and peripapillary atrophy area. Best-corrected visual acuity (BCVA) and CNV area were compared pre-treatment and post-treatment.

In 32 eyes the results were evaluated at two years and in 27 eyes they were evaluated at three years. Mean baseline BCVA significantly improved from 30.1 letters to 45.4 letters at three years. The outcome was better in eyes with juxtafoveal CNV.

A positive correlation was found between baseline BCVA and final BCVA, but there was a negative correlation for age. CNV area was reduced from 0.63 mm2 at baseline to 0.40 mm2 at the three-year follow-up. Peripapillary atrophy area was the sole contributing factor affecting the need for re-treatment.

The factors that independently correlated with the BCVA outcome were initial BCVA and age. Three monthly injections of IVB provide effective and sustained results for mCNV treatment.

The abstract can be found in the British Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.